GlobeNewswire Inc.··IpsenIpsen's IQIRVO Shows Strong Real-World Efficacy in Primary Biliary Cholangitis
Ipsen presented clinical data on IQIRVO demonstrating 59% ALP normalization and significant fatigue improvements in primary biliary cholangitis patients.
IPSEYclinical trialPPAR agonist